How adopting the decentralized trial approach introduces new challenges for companies hoping to ramp up an early phase trial or keep later stage studies going during the pandemic.

The global pandemic provides an opportunity for the further decentralization of clinical trials, with direct-to-patient protocols reducing or eliminating the need for patients to travel to clinical sites and potentially expose themselves and others to a risk of infection.​

Insight into the current level of integration between the manufacturing and supply chain used and sought by cell/gene therapy companies.

Learn strategies to improve supply chain efficiency, reduce risk and respond to local, regional and global challenges.

How Catalent’s integrated and innovative model can help to ensure timely and optimal clinical supply execution in the APAC region.

Learn ways that clinical supply strategies for late phase vary from early phase.

Strategies sponsors can enable with a supply partner in order to minimize project risk.

Cultural considerations when planning and implementing an APAC clinical supply strategy.

Summary: FastChain® demand led supply is a continuous GMP approach to secondary packaging, label printing and application, release, and regional distribution of patient kits to clinical sites based upon actual patient and site need. The FastChain® approach will...

Summary: Integrated approach from development to clinical and benefits of working with a single integrated provider.